Vivlodex FDA Approval History
Vivlodex (meloxicam) is a low dose nonsteroidal anti-inflammatory drug (NSAID) indicated for the management of osteoarthritis pain.
FDA Approval: The approval of Vivlodex was supported by data from a Phase 3, multi-center, double-blind, placebo-controlled study of 402 patients, aged 40 and older, with pain due to osteoarthritis. The Vivlodex doses studied achieved efficacy at 33 percent lower doses than currently available meloxicam products. Vivlodex is a low-dose formulation utilizing submicron particles which provide an increased surface area and faster dissolution rates. It was was developed to align with current recommendations that NSAIDs be used at the lowest effective dose for the shortest possible duration.
Mechanism: Vivlodex (meloxicam) is a nonsteroidal anti-inflammatory drug (NSAID). It works by inhibiting prostaglandin synthesis.
Dosage and Administration: Vivlodex is a capsule taken once daily without regard to timing of meals. The recommended starting dose is 5 mg, but may be increased to 10 mg in patients who require additional analgesia.
Side Effects: The most common side effects associated with Vivlodex include diarrhea, nausea, and abdominal discomfort.
Additional Information: Vivlodex comes with a Boxed Warning advising patients and healthcare professionals of the potential for nonsteroidal anti-inflammatory drugs (NSAIDs) to cause an increased risk of serious cardiovascular and gastrointestinal events.
Development Timeline for Vivlodex
|Oct 23, 2015||ApprovalFDA Approves Vivlodex (meloxicam) for Osteoarthritis Pain|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.